ANR Stock Overview
Engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Anatara Lifesciences Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.04 |
| 52 Week High | AU$0.052 |
| 52 Week Low | AU$0.021 |
| Beta | 0.62 |
| 11 Month Change | -6.98% |
| 3 Month Change | -6.98% |
| 1 Year Change | 53.85% |
| 33 Year Change | -75.00% |
| 5 Year Change | -87.30% |
| Change since IPO | -94.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANR | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 29.0% | 0.6% | -0.3% |
| 1Y | 53.8% | 7.6% | 8.3% |
Return vs Industry: ANR exceeded the Australian Biotechs industry which returned 7.6% over the past year.
Return vs Market: ANR exceeded the Australian Market which returned 8.3% over the past year.
Price Volatility
| ANR volatility | |
|---|---|
| ANR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in AU Market | 16.3% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: ANR has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ANR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | David Brookes | anataralifesciences.com |
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water.
Anatara Lifesciences Ltd Fundamentals Summary
| ANR fundamental statistics | |
|---|---|
| Market cap | AU$8.03m |
| Earnings (TTM) | -AU$1.75m |
| Revenue (TTM) | n/a |
-65.2x
P/S Ratio-4.6x
P/E RatioIs ANR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANR income statement (TTM) | |
|---|---|
| Revenue | -AU$123.18k |
| Cost of Revenue | AU$1.47m |
| Gross Profit | -AU$1.59m |
| Other Expenses | AU$157.06k |
| Earnings | -AU$1.75m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0091 |
| Gross Margin | 1,290.47% |
| Net Profit Margin | 1,417.97% |
| Debt/Equity Ratio | 0% |
How did ANR perform over the long term?
See historical performance and comparison